Context Therapeutics (CNTX) Enterprise Value (2020 - 2026)

Context Therapeutics has disclosed Enterprise Value across 7 years of filings, most recently posting -$54.5 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$54.5 million, up 38.97% year-over-year; the trailing twelve-month figure through Mar 2026 was -$54.5 million (up 38.97% YoY), and the FY2025 annual result was -$66.0 million, up 30.11% from the prior year.
• Enterprise Value came in at -$54.5 million for Q1 2026 at Context Therapeutics, up from -$66.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$10.1 million in Q1 2024 to a low of -$101.5 million in Q2 2024.
• The 5-year median for Enterprise Value is -$45.7 million (2022), against an average of -$53.9 million.
• Across the five-year window, Enterprise Value tumbled 9299.93% in 2022 and surged 66.11% in 2024, its largest moves.
• Context Therapeutics' Enterprise Value stood at -$35.5 million in 2022, then surged by 59.29% to -$14.4 million in 2023, then sank by 553.5% to -$94.4 million in 2024, then surged by 30.11% to -$66.0 million in 2025, then advanced by 17.37% to -$54.5 million in 2026.
• The last three Enterprise Value figures came in at -$54.5 million (Q1 2026), -$66.0 million (Q4 2025), and -$76.9 million (Q3 2025), per Business Quant data.